OTCPicks.com

MARINE EXPLORATION INCORPORATED (OTC: MEXP)
"Up 194.12% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/MEXP.php

Marine Exploration, Inc., a development stage company, engages in marine treasure hunting expeditions. It intends to involve in the discovery and recovery of archeologically and historically significant shipwrecks and artifacts. The company plans to sell recovered cargo and artifacts, and exhibits artifacts. It also focuses on filming and documenting its activities and the sale and distribution of those films. The company was formerly known as Multimedia K.I.D., Inc. and changed its name to SYCO, Inc. in 2006. Later, it changed its name to Marine Exploration, Inc. in April 2007. The company is based in Denver, Colorado.

MEXP News:

February 27 - Marine Exploration, Inc. Details Its Joint Venture Partner's State-of-the-Art Design, Engineering, Contracting and Development of One-of-a-Kind Magnetometer Systems for Use in Its Survey for Specific Sunken Vessels

Marine Exploration, Inc. (OTC: MEXP) reported that Burt D. Webber, Jr., at the helm of its Joint Venture Partner, Hispaniola Ventures, LLC, has worked directly with Geometrics, D&B Enterprises and Ocean Images, Inc. on the design, development and testing of two custom diver operated G-882 cesium Magnetometer systems that will be used in the survey and location of the target vessels. This system includes a newly developed wooie generator board that translates the sensor output data stream into LED numerical readout of the total magnetic field and comparable audio signals to the diver's headset.

Additionally, Webber was the innovator of the first diver operated cesium magnetometers developed by Varian & Associates in 1978. The new, one-of-a-kind Magnetometer system to be used in the Dominican Republic expedition will provide invaluable technical aids to Webber's team, the likes of which have never existed before.

FRONTIER ENERGY (OTC: FRGY)
"Up 111.11% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/FRGY.php

Frontier Energy Corporation, through its wholly owned subsidiary, Frontier Energy Resources Corp., engages in the acquisition, exploration, development, and operation of oil and gas reserves primarily in the Central Alberta region of Canada. It has 100% working interest on 160 acres of land situated in the Pembina Oil Field in Alberta, Canada. The company was founded in 1986 and is headquartered in North Las Vegas, Nevada.

FRGY News:

February 27 - Frontier Energy Corporation Adds Energy Sector Specialist George V. Bower

Frontier Energy Corporation (OTC: FRGY) (“Frontier” or the “Company”) announced the addition of George V. Bower of Strategic Business Services LLC as a consultant to the company. Mr. Bower brings with him a vast knowledge of contacts and experience, and access to many untapped natural resource opportunities, which will greatly benefit the growth of Frontier Energy.

Mr. Bower has built leading edge strategies for energy sector companies, using methods and techniques not generally found within the industry. Mr. Bower has provided his clients with previously untapped capital and growth options. Mr. Bower's clients have rewarded his contributions with large-scale venture funding commitments.

Having built a unique consulting practice in Contemporary Network Services, Mr. Bower worked as a business development contractor with such companies as Arthur D. Little, Ernst & Young, EDS Management Consulting Services, A. T. Kearney, and a variety of smaller consulting organizations. His clients include companies such as Flowserve Corp., Nutrilite, Guident Technologies, Alflex, Masco, Northrop Grumman, Teledyne, Ameron, Litton and many others.

Mr. Bower is highly qualified as a business strategist and a leading thinker in development for hyper growth companies. Mr. Bower is a qualified national strategist, graduating from the US Army War College's Defense Strategy Course in 1989 and Force Integration Course in 1991. Mr. Bower served as an assigned reserve officer in the Pentagon for seven years, where he served on the US Army staff. In addition, Mr. Bower holds a bachelor’s degree from California State Polytechnic University, San Luis Obispo, as well as an MBA from the University of Southern California.

Mr. Bob Genesi, Frontier Energy CEO, comments, “While we have worked with George in limited ways in the past, you will shortly see what that limited, yet productive, relationship has produced. We look forward to a more intense working situation. As will our shareholders.”

VICTORY ENERGY CORPORATION (OTCBB: VYEY)
"Up 75.00% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/VYEY.php

Victory Energy Corporation engages in the acquisition and development of oil and gas properties in the United States and Canada. The company primarily owns interests in the Northeast Glasgow Prospect located in Williston Basin Valley County, Montana, which consists of 1,960 acres; and the Skedee prospect in Oklahoma. It also owns joint venture interest in the Mesa gas prospect in Roosevelt County New Mexico. The company was founded in 1982 under the name All Things, Inc. and changed its name to New Environmental Technologies Corporation in 1985. Further, it changed its name to Victory Capital Holdings Corporation in 2003 and to Victory Energy Corporation in 2006. The company is based in Carson City, Nevada.

VYEY News:

February 27 - Victory Energy New Gas Well Online

Victory Energy Corporation (OTCBB: VYEY) announced the first gas well the Corporation drilled in the Adams-Baggett Canyon Sandstone gas field in Crockett County, Texas has been brought online today.

Victory's newest gas well is producing from the Canyon Sandstone gas zone. On Sunday the gas well began flowing gas to surface on its own. The well stabilized after 24 hours of sustained flow and was tied into the gas production transportation line. Sales of the gas into the market started immediately. The single point flow test has been scheduled with Fesco and actual production rates should be known by March 4.

"We are anticipating a strong production rate from this well based on its 25% higher tubing pressure than the average Canyon Sandstone gas well," stated Jon Fullenkamp, President of Victory Energy Corporation.

SHUMATE INDUSTRIES (OTCBB: SHMT)
"Up 69.23% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/SHMT.php

Shumate Industries, Inc., through its subsidiaries, operates as a contract machining and manufacturing company in the United States. It manufactures products, parts, components, and assemblies for the oil and gas field services market. The company's product line includes expandable tubing manufacturing-launchers and liner hangers for oil and gas field service applications; blowout preventers and their spare service parts; top drive assemblies, sub-assemblies, and their spare service parts; directional drilling products; exploration products for research and development; natural gas measurement equipment, including fittings and valves; control and check valves; and sub-sea control equipment. Shumate Industries also develops and commercializes the Hemiwedge Cartridge valve, a quarter-turn hemispherical wedge valve. The company was founded in 1997 and is based in Conroe, Texas.

SHMT News:

February 27 - Shumate Industries Announces Release of Innovative High Pressure, Metal-Seated Hemiwedge(R) Valve Product Line

Shumate Industries (OTCBB: SHMT) announced that its Hemiwedge Valve Corporation (HVC) division has completed development of high pressure, high flow, metal-seated valves utilizing its proprietary Hemiwedge® valve technology. The all metal-seated product line is available in ANSI / ASME Pressure Class 900, 1500, 2500, and 4500, and in 5000, 10000, 15000, 20000 psig ratings. Process connection sizes currently available are ¼” through 1”. The newly developed product line is factory tested for bi-directional zero-leakage, and available in carbon steel, stainless steel and high nickel alloys. A resilient seat option is also available.

Stan Allen, HVC’s VP of Technology and Business Development, stated, “Achieving zero leakage, bi-directional shutoff at pressures up to 20000 psig in a metal-to-metal seat design is a significant development in itself. By utilizing a variation of the Hemiwedge® sealing and operating principle, we are also able to provide a much needed product for high flow applications such as chemical injection.” Mr. Allen further stated that, “HVC anticipates use of this product in a variety of markets such as chemical, power, and conventional oil and gas production and process applications due to the ease of repair and automation.”

The high pressure, metal-seated valve line supplements the Hemiwedge® Cartridge Valve product line, which utilizes the same operating principle in ANSI / ASME B16.34 design valves in sizes 2” to 10” and pressure classes 150 to 900. The cartridge feature also permits the valve to be serviced without removing the valve body from the line, significantly reducing costly down time.

HVC’s President, Ken Chickering stated, “We completed prototype testing of the high pressure, metal-to-metal seat design in order to move forward with a licensing arrangement for sub sea applications. This same technology may also be adopted into non-sub sea applications including higher margin severe service market segments”.

Hemiwedge Valve Corporation is currently identifying strategic marketing channels for this innovative technology.

VEMICS INCORPORATED (OTC: VMCI)
"Up 42.86% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/VMCI.php

Vemics, Inc. operates as a visual communications hosted service provider. It offers software-based productivity solutions to business, education, and government available as hosted services with a focus on the education and healthcare sectors in the United States. The company's products include Vemics LiveAccess a collaboration platform that delivers video, wideband audio, and a suite of web-collaboration tools in a single browser window accessible from PCs or laptops enabling organizations and individuals to work and learn �virtually' as if everyone were in the same room; NuScribe a voice-recognition driven document creation and management system that enables physicians to create and manage patient medical records online; and iMedicore a collaborative online portal designed for and by medical professionals to facilitate practice productivity, as well as exchange of education, information, and ideas in real-time. Its education programs include Global Business English, Advanced English, Global Business Russian, Global Business Chinese, and EP LiveOnline. The company also offers various services for the healthcare sector that comprise Voice-Driven Document Creation that enables users to create notes and patient medical records using voice recognition software; ePrescribing offers drug interaction checking, formulary, electronic contact with pharmacy chains, and drug information sheets that can be printed out and sent home with the patient; and Real-time Communication and Collaboration that enables members to securely meet face-to-face online for consultations, referrals, or general communications virtually. Vemics was founded in 2001 and is based in Nanuet, New York.

VMCI News:

February 28 - iMedicor Announces Agreement with Microsoft HealthVault

Vemics, Inc (OTC: VMCI), a leading provider of hosted, real-time learning and productivity portals, announced that the Company and Microsoft Corp. (NASD: MSFT) have formalized their relationship through the execution of the Microsoft HealthVault Solution Provider agreement.

Launched in October, 2007, HealthVault is the recently announced software and services platform aimed at helping people manage and collect their personal health information. Through this agreement, Vemics’ iMedicor HIPAA compliant EHRT (Electronic Health Record Transport) portal will give HealthVault subscribers a user-friendly conduit for patient-physician communication as well as expedited access to their medical records and images.

“We, at iMedicor, are very excited to be collaborating with Microsoft HealthVault,” said Tom Dorsett, President of Healthcare Solutions for iMedicor. “From the chronically or serious ill to those needing second opinions or emergency procedures, this strategic relationship can help facilitate a better quality of medical care by enhancing the level of communication between patients and their doctors.”

“Improved communications between physicians and their patients is a critical step in empowering consumers to better manage their health and wellness,” said Peter Neupert, corporate vice president for the Health Solutions Group at Microsoft Corp. “Using Microsoft HealthVault, iMedicor will provide a central place for people and their caregivers to privately collect and share medical information, leading to better outcomes through a more collaborative and informed approach to health.”

Benefits of the new Microsoft HealthVault-iMedicor relationship include:

1) HealthVault users will be able to open up an iMedicor account through which they can communicate securely and electronically directly with their physicians.

2) Physicians with HealthVault user permission will be able to access information from the patient’s HealthVault account to upload test results, x-rays, MRIs, and other images in order to communicate and collaborate on treatment.

3) iMedicor will be listed in HealthVault’s provider page as a partner.

4) iMedicor users will also be able to open up a HealthVault account to deposit or extract personal health information.

The iMedicor portal, which went live on October 10th, is the health industry’s first free, HIPAA-compliant online personal health data exchange and secure messaging portal for physician collaboration, community and referrals. MedGadget, the influential online journal of emerging medical technologies, recently praised the portal’s simple interface and usability of the system (www.medgadget.com).

The portal’s proprietary HIPAA-compliant technology and ability to enable health providers to exchange medical record data, documentation, images, etc. are what distinguishes it from the chat-room-style portals for doctors currently in existence. Physicians, healthcare professionals and patients are all permitted to access the free site at www.iMedicor.com.

IMMUNICON CORPORATION (NASD: IMMC)
"Up 13.33% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/IMMC.php

Immunicon Corporation and its subsidiaries engage in the development, manufacture, marketing, and sale of proprietary cell-based diagnostic and research products, and services with a focus on cancer. It develops technologies that identify, count, and characterize a small number of circulating tumor cells (CTC) and other rare cells present in a blood sample of a patient. The company offers CellSave Preservative tube, an evacuated blood collection tube with preservative; CellTracks AutoPrep system, an automated instrument to capture and label cells from 7.5 ml blood samples; CellTracks MagNest Cell Presentation device, a device that presents magnetically labeled cells for analysis; CellTracks Analyzer, a semi-automated fluorescence microscope used to count and characterize cells; and CellSearch Circulating Tumor Cell kit that is used for counting CTCs. It also offers CellSearch Profile kit, which is used to isolate CTCs for subsequent molecular or cellular analysis; CellTracks Endothelial Cell kit that is used in isolating and counting endothelial cells; CellTracks Bone Marrow Tumor kit, which is used to count tumor cells in a bone marrow sample; Tumor Profiling Reagents for CTC characterization; and CellTracks CEC Profile kit that is used to isolate CECs for molecular or cell analysis. The company sells its products to hospitals, reference laboratories, oncology practices, cancer treatment centers, clinical research organizations, and pharmaceutical/biotechnology companies in the United States, Europe, Japan, and Hong Kong. Immunicon has collaboration agreements with Veridex, LLC; Diagnostic HYBRIDS, Inc.; KREATECH Biotechnology B.V.; and University of Twente and STW. The company was founded in 1983 and is based in Huntingdon Valley, Pennsylvania.

IMMC News:

February 27 - Immunicon Corporation Announces FDA Clearance of the CellSearch(TM) Circulating Tumor Cell Kit for Monitoring Patients with Metastatic Prostate Cancer

Diagnostic Test Is Now Cleared for Three of the Four Most Common Cancers

Immunicon Corporation (NASD: IMMC) announced that the FDA has cleared the CellSearch™ Circulating Tumor Cell (CTC) Kit as an aid in the monitoring of patients with metastatic prostate cancer. A sample of the patient’s blood is processed with the CellSearch Kit using the CellTracks® System to capture and count CTCs. This clearance represents another expansion to claims for the kit, which is now cleared for three of the four most prevalent cancers. The CellSearch CTC kit was originally cleared in January 2004 to predict progression-free and overall survival in patients with metastatic breast cancer and later expanded to include monitoring. In November 2007, the kit was cleared by the FDA for monitoring metastatic colorectal cancer.

Byron D. Hewett, CEO and President of Immunicon Corporation, commented, "Because the three pivotal trials demonstrated that the CellSearch test predicts survival in prostate, breast and colorectal cancers, circulating tumor cell testing should become standard of care in the management of patients with metastatic disease. We estimate the market size for testing in these three cancers is almost $1 billion. More importantly, oncologists can use the results to make better-informed treatment decisions and improve patient care for three of the top carcinomas.”

THE IMPACT

According to the American Cancer Society, prostate cancer claims approximately 27,000 lives each year, the vast majority of which are a result of recurrent metastatic disease. Metastatic prostate cancer occurs when tumor cells spread to other locations in the body and grow. Evaluation of CTC count at any time during the treatment of metastatic disease allows assessment of patient prognosis and predicts survival. Oncologists often have to wait several months before they can determine if a specific treatment is beneficial to the patient. Changes in CTC count can be assessed in 3-5 weeks, rather than in the 8-12 weeks required for imaging studies such as CT scans. The results of serial CTC testing can help physicians assess disease progression, thereby guiding more informed patient care decisions earlier.

THE RESULTS

The study demonstrated that a threshold of 5 CTC / 7.5 mL stratifies androgen independent prostate cancer patients into two distinct groups based on comparison to overall survival (OS). Patients with 5 or more CTCs at baseline and at 3-4 weeks after the initiation of chemotherapy have significantly shorter OS than patients with less than 5 CTCs. The presence of CTCs at any time during the course of the disease is a strong independent predictor of OS. The CellSearch test provides more reliable and informative results regarding the biological activity of the individual patient’s disease status than do measurements of PSA. Although a reduction of PSA at some points after initiation of therapy may reach significance for prediction of survival, favorable CTC at any time point were more accurate than the PSA evaluation. The practical implication is the use of CTC analysis for the evaluation of the probability of survival of patients with metastatic prostate cancer. In cases where CTC and PSA change were discordant, CTC change provided the most accurate assessment of prognosis.

Finally, the fundamental principles of tumor biology upon which the CellSearch test is based are common to all three diseases. Consequently, results from each study demonstrate that a CTC threshold exists in these carcinomas and can be used to stratify patients based on the demonstrated agreement of CTC with the true clinical end point overall survival.

For more details on the results of this prostate cancer trial, please refer to the press release section of the Immunicon web site (immunicon.com) and download the release entitled "Immunicon Achieves Endpoint in its Pivotal Clinical Trial in Metastatic Androgen Independent Prostate Cancer" posted on January 18, 2007.

The CellSearch Circulating Tumor Cell Kit was developed by Immunicon and is exclusively marketed by Veridex, LLC, in the cancer field.